Pumpless Extracorporeal Hemadsorption Technique (pEHAT) : A Proof-of-Concept Animal Study
Background: Extracorporeal hemadsorption eliminates proinflammatory mediators in critically ill patients with hyperinflammation. The use of a pumpless extracorporeal hemadsorption technique allows its early usage prior to organ failure and the need for an additional medical device. In our animal model, we investigated the feasibility of pumpless extracorporeal hemadsorption over a wide range of mean arterial pressures (MAP). Methods: An arteriovenous shunt between the femoral artery and femoral vein was established in eight pigs. The hemadsorption devices were inserted into the shunt circulation; four pigs received CytoSorb® and four Oxiris® hemadsorbers. Extracorporeal blood flow was measured in a range between mean arterial pressures of 45-85 mmHg. Mean arterial pressures were preset using intravenous infusions of noradrenaline, urapidil, or increased sedatives. Results: Extracorporeal blood flows remained well above the minimum flows recommended by the manufacturers throughout all MAP steps for both devices. Linear regression resulted in CytoSorb® blood flow [mL/min] = 4.226 × MAP [mmHg] - 3.496 (R-square 0.8133) and Oxiris® blood flow [mL/min] = 3.267 × MAP [mmHg] + 57.63 (R-square 0.8708), respectively. Conclusion: Arteriovenous pumpless extracorporeal hemadsorption resulted in sufficient blood flows through both the CytoSorb® and Oxiris® devices over a wide range of mean arterial blood pressures and is likely an intriguing therapeutic option in the early phase of septic shock or hyperinflammatory syndromes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 11(2022), 22 vom: 18. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fiedler, Mascha O [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 13.12.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm11226815 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349442436 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349442436 | ||
| 003 | DE-627 | ||
| 005 | 20231226042632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11226815 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349442436 | ||
| 035 | |a (NLM)36431292 | ||
| 035 | |a (PII)6815 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fiedler, Mascha O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pumpless Extracorporeal Hemadsorption Technique (pEHAT) |b A Proof-of-Concept Animal Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Background: Extracorporeal hemadsorption eliminates proinflammatory mediators in critically ill patients with hyperinflammation. The use of a pumpless extracorporeal hemadsorption technique allows its early usage prior to organ failure and the need for an additional medical device. In our animal model, we investigated the feasibility of pumpless extracorporeal hemadsorption over a wide range of mean arterial pressures (MAP). Methods: An arteriovenous shunt between the femoral artery and femoral vein was established in eight pigs. The hemadsorption devices were inserted into the shunt circulation; four pigs received CytoSorb® and four Oxiris® hemadsorbers. Extracorporeal blood flow was measured in a range between mean arterial pressures of 45-85 mmHg. Mean arterial pressures were preset using intravenous infusions of noradrenaline, urapidil, or increased sedatives. Results: Extracorporeal blood flows remained well above the minimum flows recommended by the manufacturers throughout all MAP steps for both devices. Linear regression resulted in CytoSorb® blood flow [mL/min] = 4.226 × MAP [mmHg] - 3.496 (R-square 0.8133) and Oxiris® blood flow [mL/min] = 3.267 × MAP [mmHg] + 57.63 (R-square 0.8708), respectively. Conclusion: Arteriovenous pumpless extracorporeal hemadsorption resulted in sufficient blood flows through both the CytoSorb® and Oxiris® devices over a wide range of mean arterial blood pressures and is likely an intriguing therapeutic option in the early phase of septic shock or hyperinflammatory syndromes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adsorption | |
| 650 | 4 | |a animal model | |
| 650 | 4 | |a arteriovenous extracorporeal hemadsorption technique | |
| 650 | 4 | |a blood purification | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a endotoxin | |
| 650 | 4 | |a extracorporeal hemadsorption | |
| 650 | 4 | |a extracorporeal techniques in hemadsorption therapy | |
| 650 | 4 | |a immunosorbents | |
| 650 | 4 | |a septic shock | |
| 700 | 1 | |a Muellenbach, Ralf M |e verfasserin |4 aut | |
| 700 | 1 | |a Rolfes, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Lotz, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Nickel, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Müller-Stich, Beat P |e verfasserin |4 aut | |
| 700 | 1 | |a Supady, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Lepper, Philipp M |e verfasserin |4 aut | |
| 700 | 1 | |a Weigand, Markus A |e verfasserin |4 aut | |
| 700 | 1 | |a Meybohm, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Kalenka, Armin |e verfasserin |4 aut | |
| 700 | 1 | |a Reyher, Christian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 11(2022), 22 vom: 18. Nov. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:22 |g day:18 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm11226815 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 22 |b 18 |c 11 | ||